Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
Login
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
Organization
Job Role
Country
Catalog Type
Product Name
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
C57BL/6JCya-Frg1em1/Cya
Common Name:
Frg1-KO
Product ID:
S-KO-02117
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Frg1-KO
Strain ID
KOCMP-14300-Frg1-B6J-VB
Gene Name
Frg1
Product ID
S-KO-02117
Gene Alias
--
Background
C57BL/6JCya
NCBI ID
14300
Modification
Conventional knockout
Chromosome
8
Phenotype
MGI:893597
Document
Click here to download >>
Application
--
More
Rare Disease Data Center >>
Note
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Frg1em1/Cya mice (Catalog S-KO-02117) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000033999
NCBI RefSeq
NM_013522
Target Region
Exon 3~4
Size of Effective Region
~1.9 kb
Detailed Document
Click here to download >>
Overview of Gene Research
FRG1, short for FSHD region gene 1, is the primary candidate gene for Fascioscapulohumeral Muscular Dystrophy (FSHD). It has been implicated in multiple physiological processes. Mechanistically, it may play a role in RNA biogenesis, influencing pathways like mRNA surveillance, RNA transport, and spliceosome machinery [1]. It is also associated with processes such as muscle development, vasculogenesis, angiogenesis, and tumorigenesis [1,2,3,4,5,6,7,8]. Genetic models, like those in Xenopus laevis and mouse myoblasts, have been valuable in studying its functions [7,9].

In terms of specific findings, in Xenopus laevis, frg1 is expressed in and essential for tadpole musculature development. Disrupting its expression led to myotome organization and growth defects, while overexpression caused abnormal muscle formation, suggesting its crucial role in proper muscle development [7]. In mouse myoblasts overexpressing FRG1, decreased proliferation was observed, which may contribute to the pathology of FSHD [9]. In cancer studies, reduced FRG1 expression promoted angiogenesis via the FGF2-mediated ERK/AKT pathway in breast cancer [2], and in prostate cancer, it affected cell migration and invasion, likely through p38 MAPK activation [4]. FRG1 also seems to play a role in DNA repair in breast cancer, with low expression associated with reduced DNA repair capabilities and a higher frequency of TP53 mutation [3].

In conclusion, FRG1 is vital for muscle development and has significant implications in angiogenesis, tumorigenesis, and DNA repair. Studies using genetic models, especially in muscle-related and cancer-related disease areas, have revealed its multifaceted functions. Understanding FRG1 can potentially provide insights into the pathophysiology of FSHD and cancer, offering new directions for therapeutic strategies.

References:

1. Palo, Ananya, Patel, Saket Awadhesbhai, Sahoo, Bibekananda, Chowdary, Tirumala Kumar, Dixit, Manjusha. 2022. FRG1 is a direct transcriptional regulator of nonsense-mediated mRNA decay genes. In Genomics, 115, 110539. doi:10.1016/j.ygeno.2022.110539. https://pubmed.ncbi.nlm.nih.gov/36521634/

2. Mukherjee, Bratati, Brahma, Pratush, Mohapatra, Talina, Chawla, Saurabh, Dixit, Manjusha. 2023. Reduced FRG1 expression promotes angiogenesis via activation of the FGF2-mediated ERK/AKT pathway. In FEBS open bio, 13, 804-817. doi:10.1002/2211-5463.13582. https://pubmed.ncbi.nlm.nih.gov/36815234/

3. Shubhanjali, Shubhanjali, Mohapatra, Talina, Khan, Rehan, Dixit, Manjusha. 2024. Unveiling FRG1's DNA repair role in breast cancer. In Scientific reports, 14, 19371. doi:10.1038/s41598-024-70368-9. https://pubmed.ncbi.nlm.nih.gov/39169067/

4. Tiwari, Ankit, Mukherjee, Bratati, Hassan, Md Khurshidul, Jaiswal, Archita Mohanty, Dixit, Manjusha. 2019. Reduced FRG1 expression promotes prostate cancer progression and affects prostate cancer cell migration and invasion. In BMC cancer, 19, 346. doi:10.1186/s12885-019-5509-4. https://pubmed.ncbi.nlm.nih.gov/30975102/

5. Mukherjee, Bratati, Tiwari, Ankit, Palo, Ananya, Samantara, Subrat, Dixit, Manjusha. 2022. Reduced expression of FRG1 facilitates breast cancer progression via GM-CSF/MEK-ERK axis by abating FRG1 mediated transcriptional repression of GM-CSF. In Cell death discovery, 8, 442. doi:10.1038/s41420-022-01240-w. https://pubmed.ncbi.nlm.nih.gov/36329016/

6. DeSimone, Alec M, Pakula, Anna, Lek, Angela, Emerson, Charles P. 2017. Facioscapulohumeral Muscular Dystrophy. In Comprehensive Physiology, 7, 1229-1279. doi:10.1002/cphy.c160039. https://pubmed.ncbi.nlm.nih.gov/28915324/

7. Hanel, Meredith L, Wuebbles, Ryan D, Jones, Peter L. . Muscular dystrophy candidate gene FRG1 is critical for muscle development. In Developmental dynamics : an official publication of the American Association of Anatomists, 238, 1502-12. doi:10.1002/dvdy.21830. https://pubmed.ncbi.nlm.nih.gov/19097195/

8. Hansda, Arman Kunwar, Tiwari, Ankit, Dixit, Manjusha. . Current status and future prospect of FSHD region gene 1. In Journal of biosciences, 42, 345-353. doi:. https://pubmed.ncbi.nlm.nih.gov/28569257/

9. Chen, Steven C, Frett, Ellie, Marx, Joseph, Kyba, Michael, Kennedy, Brian K. 2011. Decreased proliferation kinetics of mouse myoblasts overexpressing FRG1. In PloS one, 6, e19780. doi:10.1371/journal.pone.0019780. https://pubmed.ncbi.nlm.nih.gov/21603621/

Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest